US45337C1027 - Common Stock

We assign a fundamental rating of **6** out of 10 to **INCY**. **INCY** was compared to 564 industry peers in the **Biotechnology** industry. Both the health and profitability get an excellent rating, making **INCY** a very profitable company, without any liquidiy or solvency issues. **INCY** has a decent growth rate and is not valued too expensively. These ratings would make **INCY** suitable for quality investing!

In the past year **INCY** was profitable.

Of the past 5 years **INCY** 4 years were profitable.

With an excellent **Return On Assets** value of **0.65%**, **INCY** belongs to the best of the industry, outperforming **92.69%** of the companies in the same industry.

With an excellent **Return On Equity** value of **1.02%**, **INCY** belongs to the best of the industry, outperforming **93.76%** of the companies in the same industry.

The last **Return On Invested Capital** (**0.38%**) for **INCY** is well below the 3 year average (**9.11%**), which needs to be investigated, but indicates that **INCY** had better years and this may not be a problem.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.65% | ||

ROE | 1.02% | ||

ROIC | 0.38% |

ROA(3y)11.29%

ROA(5y)7.72%

ROE(3y)14.82%

ROE(5y)10.07%

ROIC(3y)9.11%

ROIC(5y)N/A

The **Profit Margin** of **INCY** (**0.80%**) is better than **93.05%** of its industry peers.

The **Gross Margin** of **INCY** (**93.37%**) is better than **95.01%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 0.48% | ||

PM (TTM) | 0.8% | ||

GM | 93.37% |

OM growth 3YN/A

OM growth 5Y16.39%

PM growth 3YN/A

PM growth 5Y22.68%

GM growth 3Y-0.76%

GM growth 5Y-0.51%

The number of shares outstanding for **INCY** has been increased compared to 1 year ago.

The Debt to FCF ratio of **INCY** is **1.05**, which is an excellent value as it means it would take **INCY**, only **1.05** years of fcf income to pay off all of its debts.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.01 | ||

Debt/FCF | 1.05 | ||

Altman-Z | 6.02 |

ROIC/WACC0.04

WACC10.26%

A Current Ratio of **1.87** indicates that **INCY** should not have too much problems paying its short term obligations.

With a **Current ratio** value of **1.87**, **INCY** is not doing good in the industry: **78.07%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.87 | ||

Quick Ratio | 1.82 |

The earnings per share for **INCY** have decreased strongly by **-69.16%** in the last year.

Looking at the last year, **INCY** shows a quite strong growth in **Revenue**. The Revenue has grown by **12.94%** in the last year.

Measured over the past years, **INCY** shows a quite strong growth in **Revenue**. The Revenue has been growing by **14.45%** on average per year.

EPS 1Y (TTM)-69.16%

EPS 3YN/A

EPS 5Y27.86%

EPS Q2Q%-2.73%

Revenue 1Y (TTM)12.94%

Revenue growth 3Y11.49%

Revenue growth 5Y14.45%

Sales Q2Q%23.81%

Based on estimates for the next years, **INCY** will show a quite strong growth in **Revenue**. The Revenue will grow by **8.74%** on average per year.

EPS Next Y-62.16%

EPS Next 2Y33.39%

EPS Next 3Y30.93%

EPS Next 5Y17.88%

Revenue Next Year13.95%

Revenue Next 2Y12.14%

Revenue Next 3Y11.68%

Revenue Next 5Y8.74%

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

Based on the **Price/Earnings** ratio, **INCY** is valued cheaper than 94.30% of the companies in the same industry.

With a **Price/Forward Earnings** ratio of **13.31**, **INCY** is valued correctly.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **INCY** indicates a rather cheap valuation: **INCY** is cheaper than 97.33% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 87.77 | ||

Fwd PE | 13.31 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **INCY** indicates a rather cheap valuation: **INCY** is cheaper than 93.40% of the companies listed in the same industry.

Based on the **Price/Free Cash Flow** ratio, **INCY** is valued cheaply inside the industry as 92.87% of the companies are valued more expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 524.24 | ||

EV/EBITDA | 128.62 |

The excellent profitability rating of **INCY** may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)3.15

EPS Next 2Y33.39%

EPS Next 3Y30.93%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**INCYTE CORP**

NASDAQ:INCY (11/8/2024, 8:00:19 PM)

After market: 83.38 0 (0%)**83.38**

**+1.04 (+1.26%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap16.06B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 87.77 | ||

Fwd PE | 13.31 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)3.15

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 0.65% | ||

ROE | 1.02% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 0.48% | ||

PM (TTM) | 0.8% | ||

GM | 93.37% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.81

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.01 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.87 | ||

Quick Ratio | 1.82 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-69.16%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-62.16%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)12.94%

Revenue growth 3Y11.49%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y